This page has been archived on the Web

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

Archived

This page has been archived on the Web.

Health product recall

Paclitaxel for Injection

Starting date:
May 31, 2013
Posting date:
June 19, 2013
Type of communication:
Drug Recall
Subcategory:
Drugs
Hazard classification:
Type II
Source of recall:
Health Canada
Issue:
Product Safety
Audience:
General Public, Healthcare Professionals, Hospitals
Identification number:
RA-34251

Recalled products

  1. Paclitaxel for Injection

Reason

Recall due to inadvertent re-release of lots involved in the investigation of customer complaints received outside of Canada for visual vial defects which resemble a rust-like mark at the neck of the vial or black particles close to the neck of the vial.

Depth of distribution

Wholesalers, hospitals and pharmacies in Canada.

Affected products

A. Paclitaxel for Injection

DIN, NPN, DIN-HIM
DIN 02296624
Dosage form
  • Solution
Strength
  • 300 mg / 50 mL ( 6 mg/mL)
Lot or serial number
  • Y046843AB
  • Y056843AF
  • Y076847AB
Companies
Recalling Firm
Hospira Healthcare Corporation
600 - 1111 Dr. Frederik-Philips Blvd.
Saint-Laurent
H4M 2X6
Quebec
CANADA
Marketing Authorization Holder
Hospira Healthcare Corporation
600 - 1111 Dr. Frederik-Philips Blvd.
Saint-Laurent
H4M 2X6
Quebec
CANADA

Date modified: